Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.

ABSTRACT:

Background

Autologous mesenchymal stem cell neurotrophic factor-secreting cells (NurOwn^®) have the potential to modify underlying disease mechanisms in progressive multiple sclerosis (PMS).

Objective

This open-label phase II study was conducted to evaluate safety/efficacy of three intrathecal cell treatments.

Methods

Eighteen participants with non-relapsing PMS were treated. The primary endpoint was safety. Secondary endpoints included: cerebrospinal fluid (CSF) biomarkers; timed 25-foot walk speed, nine-hole peg test (9-HPT), low-contrast letter acuity, symbol digit modalities test, and 12-item multiple sclerosis (MS) walking scale. Seventeen participants received all treatments.

Results

No deaths/adverse events related to worsening of MS, clinical/

SUBMITTER: Cohen JA 

PROVIDER: S-EPMC9896300 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature